<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03830671</url>
  </required_header>
  <id_info>
    <org_study_id>2018ZX10722301-001</org_study_id>
    <nct_id>NCT03830671</nct_id>
  </id_info>
  <brief_title>The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB</brief_title>
  <official_title>The Effect of New MDR-TB Regimen With 18 Month Duration Containing 6 Anti-tuberculosis Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chest Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      WHO has recommended that multidrug-resistant tuberculosis (MDR-TB, defined as resistance to
      at least isoniazid (H) and rifampicin (R) be addressed as a public health crisis and enhance
      capacity to deliver effective treatment and care. According to the 2018 WHO TB Report, the
      overall treatment success rate of MDR-TB is 55% while much lower in China at just only 41%
      with the 24-month regimen. In order to further verify the safety and efficiency of optimizing
      shorter 18-month regimen containing 6 anti-TB drugs with MDR-TB patients,500 more patients
      will be enrolled and observed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Design: the study is a multi-center,open, single arm trial.

        2. Population:patients with sputum culture positive and confirmed as MDR-TB via drug
           resistance of isoniazid(H),rifampicin(R),ethambutol(E)and pyrazinamide or patients with
           GeneXpert confirmed RR-TB.

        3. Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are
           the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated
           drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium
           para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The
           abbreviation of the name of the 3 drugs in the regimen is explained as follows:
           PZA—pyrazinamide，Am—Amikacin，Mfx—moxifloxacin）and the total duration of the regimen is
           18 months.

        4. Primary and secondary outcome measures:

           The primary outcome measures include 1.the treatment success rate.2. Death rate.

           The secondary outcome measures include 1.sputum conversion rate at the end of month 2,
           month 3,intensive phase of 6 months and treatment completion of all enrolled
           patients.2.Frequency of adverse drug reaction occurring during treatment.3.Radiological
           manifestation change of TB lesion or cavity during treatment.

        5. Sample size: 500 eligible patients will be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the treatment success rate</measure>
    <time_frame>at the end of treatment completion of all enrolled patients,an average of 18 months after the last patient enrolled</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>death rate</measure>
    <time_frame>at the end of treatment completion of all enrolled patients, an average of 18 months after the last patient enrolled</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>sputum conversion rate at the end of month 2, month 3,intensive phase and treatment completion.</measure>
    <time_frame>at the end of month 2, month 3,intensive phase of 6 months since treatment initiation and treatment completion of all enrolled patients, an average of 18 months after the last enrolled patient.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse drug reaction occurring during treatment.</measure>
    <time_frame>at the end of treatment completion of all enrolled patients, an average of 18 months after the last enrolled patient.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological manifestation change of TB lesion or cavity at the end of month 2, month 3,intensive phase and treatment completion.</measure>
    <time_frame>at the end of month 2, month 3,intensive phase of 6 months since treatment initiation and treatment completion of all enrolled patients, an average of 18 months after the last enrolled patient.</time_frame>
    <description>proportion of lung field the lesion accumulated taken up at different time points with the comparison to that at baseline. The number and size of cavities at different time points with comparison to that at baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Multi-drug Resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>investigational arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the arm was given investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA—pyrazinamide，Am—Amikacin，Mfx—moxifloxacin）and the total duration of the regimen is 18 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18-month regimen containing 6 anti-TB drugs</intervention_name>
    <description>Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA—pyrazinamide，Am—Amikacin，Mfx—moxifloxacin）and the total duration of the regimen is 18 months</description>
    <arm_group_label>investigational arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is willing and able to give informed consent to participate in the trial treatment and
             follow-up.

          -  Is aged between 18 years and 70 years.

          -  Has a positive sputum culture result or a positive GeneXpert result.

          -  Has evidence of RR-TB or MDR-TB either by GeneXpert or culture-based drug
             susceptibility testing (DST).

          -  Non pre-XDR-TB or XDR-TB.

          -  Is willing to use effective contraception of women at childbearing age.

          -  Has had a chest X-ray that is compatible with a diagnosis of pulmonary TB.

        Exclusion Criteria:

          -  pre-XDR-TB or XDR-TB.

          -  Has a known allergy to any drug of the regimen.

          -  Is currently taking or took part in another trial less than three months before the
             study initiation .

          -  Is HIV positive.

          -  Has abnormal ECG with QT prolongation over 430ms of men while 450 of women.

          -  Is critically ill, and in the judgment of the investigator, unlikely to take part in
             the study.Or has any condition (social or medical) which in the opinion of the
             investigator would make study participation unsafe.

          -  Is known to be pregnant or breast-feeding.

          -  Has severe cardiovascular diseases, such as heart failure, hypertension (poor blood
             pressure control), arrhythmia or post-infarction status.

          -  Has severe concomitant severe disease such as respiratory failure or cardiac
             insufficiency or liver and kidney injury with aspartate aminotransferase (AST) or
             alanine aminotransferase (ALT) more than 2.5 times the upper limit of normal or with
             serum creatinine(Cr)more than 1.3 times the upper limit of normal.

          -  Has Karnofsky score less than 50%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qi Li</last_name>
    <phone>86-10-89509131</phone>
    <email>lq0703@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Chest Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mengqiu Gao</last_name>
    </contact>
    <investigator>
      <last_name>Mengqiu Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 8th Medical Center of Chinese Pla General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianqin Liang</last_name>
    </contact>
    <investigator>
      <last_name>Jianqin Liang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changchun Infectious Disease Hospital</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun Wu</last_name>
    </contact>
    <investigator>
      <last_name>Chun Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Institute For Tuberculosis Control</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunyun Yang</last_name>
    </contact>
    <investigator>
      <last_name>Hengzhong Yi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Public Health Clinical Center of Chengdu</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guihui Wu</last_name>
    </contact>
    <investigator>
      <last_name>Guihui Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Third Peple's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guobao Li</last_name>
    </contact>
    <investigator>
      <last_name>Guobao Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Chest Hospital</name>
      <address>
        <city>Guanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shouyong Tan</last_name>
    </contact>
    <investigator>
      <last_name>Shouyong Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Du</last_name>
    </contact>
    <investigator>
      <last_name>Juan Du</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Prevention Hospital in Heilongjiang Province</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuqin Liu</last_name>
    </contact>
    <investigator>
      <last_name>Yuqin Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anhui Chest Hospital</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaohong Kan</last_name>
    </contact>
    <investigator>
      <last_name>Xiaohong Kan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth People's Hospital of Inner Mongolia Autonomous region</name>
      <address>
        <city>Hohhot</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Gao</last_name>
    </contact>
    <investigator>
      <last_name>Fei Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Chest Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihua Qiu</last_name>
    </contact>
    <investigator>
      <last_name>Lihua Qiu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Fan</last_name>
    </contact>
    <investigator>
      <last_name>Lin Fan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenyang Chest Hospital</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Chen</last_name>
    </contact>
    <investigator>
      <last_name>Wei Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Haihe Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shifeng Shao</last_name>
    </contact>
    <investigator>
      <last_name>Shifeng Shao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Tuberculosis Prevention and Treatment Hospital of Shanxi Province</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qianhong Wu</last_name>
    </contact>
    <investigator>
      <last_name>Qianhong Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xi'an Chest Hospital</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mengtao Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Mengtao Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth People's Hospital of Ningxia Autonomous Region</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Xu</last_name>
    </contact>
    <investigator>
      <last_name>Lin Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Infectious Disease Hospital of Wangkai Zaozhuang</name>
      <address>
        <city>Zaozhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cunchuan Li</last_name>
    </contact>
    <investigator>
      <last_name>Cunchuan Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC</name>
      <address>
        <city>Ürümqi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuerman Xiayizhati</last_name>
    </contact>
    <investigator>
      <last_name>Kuerman Xiayizhati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>February 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2019</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chest Hospital</investigator_affiliation>
    <investigator_full_name>Qi Li</investigator_full_name>
    <investigator_title>Director of Tuberculosis Clinical Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

